• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
Campylobacter bacteria

Developing a biologic to prevent gastrointestinal diseases

The Naval Medical Research Center (NMRC) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) recently established an agreement with Lumen Bioscience, located in Seattle, to develop a new immunotherapy to prevent gastrointestinal diseases caused by Campylobacter jejuni and enterotoxigenic E. coli (ETEC).

Read more →
Caliper Ingredients

Caliper Ingredients Deliver CBD Into The Bloodstream Significantly Faster - Up To 424 Times Faster Than Isolate and Up To 64 Times Faster Than Tinctures

Caliper Ingredients (Caliper), a leading manufacturer and supplier of soluble cannabinoid ingredients, in conjunction with Colorado State University (CSU), has completed the CBD industry's first human clinical study of commercially available CBD-infused food and supplement product pharmacokinetics.

Read more →
GoldenBiotech's New Drug Antroquinono

Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC

Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Phase 2 clinical trial and signed first agreement in global licensing progress. GoldenBiotech receives in Jan.

Read more →
Chengdu Kanghong Pharmaceutical Group

More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept

Chengdu Kanghong Pharmaceutical Group ("Kanghong", SHE: 002773), has received Special Protocol Assessments from the Food and Drug Administration for three new indications for its biologic drug conbercept. The drug is an anti-VEGF fusion protein, approved and marketed in China as Lumitin®, for the treatment of retinal diseases.

Read more →
The Feinstein Institutes for Medical Research

Northwell Health and Cold Spring Harbor Laboratory open virtual COVID-19 clinical trial for non-hospitalized patients

The Feinstein Institutes for Medical Research and Cold Spring Harbor Laboratory (CSHL) are recruiting patients in a fully virtual, in-home, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of famotidine, or PEPCID, for the outpatient treatment of the novel coronavirus disease 2019 (COVID-19) in adults.

Read more →

We use cookies to ensure you get the best experience on this website Privacy Policy